Skip to main content
Clinical Trials/NCT05969925
NCT05969925
Not yet recruiting
Not Applicable

Study of Some Biomarkers Of Heart Failure In Children Attending Pediatric Cardiology Department Of Assiut University Children Hospital

Ahmed Ali Mahny0 sites70 target enrollmentSeptember 1, 2023
ConditionsHeart Failure

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Ahmed Ali Mahny
Enrollment
70
Primary Endpoint
serum level of Neutrophil gelatinase-associated lipocalin in pediatric heart failure
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Heart failure (HF) is a clinical syndrome where the heart is unable to pump the blood required to meet the metabolic demands of the body. Heart failure in children can result from a variety of structural or functional cardiac disorders with subsequent failure of the ventricles to fill with or eject blood

Detailed Description

Cardiac biomarkers are useful as diagnostic and prognostic tools, especially in patients with atypical signs and symptoms. High rate of complication in HF led to the search for suitable cardiac biomarker that diagnose heart failure as early as possible, predict outcome, reflect response to treatment and help in staging of heart failure and determine risk (6) . In pediatrics, biomarkers of heart failure are particularly important for the early identification and risk stratification of patients with systemic diseases and associated risk for early development of heart failure. Good biomarkers have the following characteristics: high sensitivity and specificity, the possibility of simultaneous processing of many samples, short analysis time, low cost, and good clinical applications, thus predicting the risk of heart failure and the associated prognosis as well as the adequacy of monitoring \[7\]. . Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa protein covalently bound to matrix metalloproteinase-9 which was first isolated from neutrophils. It belongs to the lipocalin family, NGAL has been found to be elevated in both plasma and urine in patients with HF.(8) NGAL also acts as a growth and differentiation factor in the renal epithelium \[9\].

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
September 2, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Ahmed Ali Mahny
Responsible Party
Sponsor Investigator
Principal Investigator

Ahmed Ali Mahny

Specialist, Pediatric Hospital

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

serum level of Neutrophil gelatinase-associated lipocalin in pediatric heart failure

Time Frame: one year

accuarcy of serum level of Neutrophil gelatinase-associated lipocalin in heart failure

Similar Trials